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Baseline analysis of renal function in the Diabetes Control and Com-
plications Trial. To determine whether there are relationships between
nephropathy, retinopathy and putative risk factors at points very early
in the development of long-term complications of IDDM, we have
analyzed baseline data pertinent to nephropathy in the 726 subjects in
the primary prevention cohort and the 715 subjects in the secondary
intervention cohort of the DCCT. AER conelated positively with Ccr
and HbAIC in both cohorts and with degree of retinopathy and duration
of IDDM in the secondary cohort. Within the secondary cohort only
mean BP and HbAIC levels were significantly increased (P < 0.005) in
the 73 subjects with AER  28 sg/24 hr compared to the 642 subjects
with AER < 28 pg/24 hr. Stratification of all subjects in the secondary
cohort showed significant associations (P < 0.001) between retinopathy
level, AER, duration of diabetes at entry and entry HbA,O, Even very
early in the development of retinopathy and nephropathy, there is a
relationship between them and with level of metabolic control. The
prospective studies of the DCCT are designed to answer the question of
whether intensive diabetes treatment will affect the development and/or
progression of retinopathy, and, possibly, of nephropathy.
Diabetic nephropathy accounts for 25 to 30% of patients with
end-stage renal disease requiring dialysis [1—3], and it has been
estimated that 30 to 40% of patients with insulin dependent
diabetes mellitus (IDDM) will eventually develop end-stage
renal disease [4—6]. A number of factors may interact in the
pathogenesis of diabetic nephropathy, including metabolic,
hemodynamic and, as yet poorly defined genetic and/or envi-
ronmental determinants.
The Diabetes Control and Complications Trial (DCCT) is an
NIH-sponsored, multicenter (29 centers), randomized clinical
trial comparing the effects of intensive insulin treatment, de-
signed to achieve blood glucose levels as close to normal as
possible while minimizing hypoglycemia, with conventional
diabetes treatment on the development and progression of the
chronic complications of IDDM [7]. The DCCT includes two
distinct studies: the primary prevention trial examines whether
intensive treatment affects the initial development and subse-
quent progression of complications in subjects who have no
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evidence of diabetic retinopathy at baseline; the secondary
intervention trial examines whether intensive treatment of
diabetes affects the rate of progression of complications in
subjects who have evidence of minimal retinopathy at baseline.
We present an analysis of baseline data pertinent to nephrop-
athy in the 1441 generally healthy subjects with IDDM entered
into the DCCT [8]. Because an increase in urinary albumin
excretion rate (AER) has been suggested as the earliest mani-
festation or a marker of diabetic nephropathy in previous
reports [9—12], we examined this parameter in our two cohorts,
analyzing its relationship to other aspects of renal function,
diabetes control and established and putative risk factors for
diabetic nephropathy. In these previous reports, patients had
long duration of diabetes and usually other concomitant com-
plications that may have been quite advanced, such as retinop-
athy and hypertension. Because our subjects are at a point
much earlier in the course of the development of these compli-
cations, we have examined the hypothesis that retinopathy and
nephropathy are linked by common etiological mechanisms.
We have also explored the importance of various risk factors
established or proposed for more advanced nephropathy, such
as glycemic level, blood pressure, serum cholesterol, dietary
protein intake, and family history of nephropathy and hyper-
tension at this very early point in the development of diabetic
complications.
Methods
Patients
A detailed description of the eligibility criteria and random-
ization procedures for subjects entering the DCCT has been
published [7]. At randomization all subjects were 13 to 39 years
of age and had a duration of IDDM of 1 to 15 years. They were
free of advanced micro- or macrovascular complications of
diabetes, normotensive (BP <140/90 mm Hg), suffered from no
other significant medical or psychiatric disorders that might
complicate their care or limit their participation in the study,
were free of neuropathy of sufficient magnitude to require
symptomatic treatment and had fasting C-peptide levels < 0.2
nmollliter and low density lipoprotein (LDL) cholesterol levels
<4.91 mmol/liter. In addition, a Sr < 106 smol/liter and/or Ce,.
> 100 mi/mm/i .73m2) were required. A history of nondiabetic
renal disease was an exclusion criterion. Subjects with a history
of heavy alcohol consumption within the past five years or
regular use of analgesics were also excluded.
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had the following additional selection characteristics at entry
into the study: duration of IDDM 1 to 5 years, no retinopathy
visible on seven field stereo fundus photography, urinary AER
<28 g/min and stimulated C-peptide levels  0.5 nmol/liter.
The cutoff value of 28 jsglmin for AER is in the middle of the
range of values cited as being "predictive" of clinical nephrop-
athy [9—12]. The secondary intervention cohort consists of 715
subjects who had the following additional selection character-
istics at entry into the study: minimal retinopathy (< P2 by
modified Airlie House criteria [13]) visible on stereo fundus
photography, urinary AER 139 g/min and stimulated C-pep-
tide levels 0.2 nmol/liter. All eligibility determinations were
completed within a four month period prior to that subject's
randomization. A history of prior urinary tract infections re-
quiring antibiotics and of parental hypertension was recorded at
entry into the study.
Assessment of blood pressure and renal function
Blood pressure was measured in the right arm in the sitting
position after the subject had been resting for at least five
minutes in a quiet room using a standard (adjusted for arm size),
manually inflated cuff and a mercury manometer, readings
being determined to the nearest even number. The disappear-
ance of sounds (Korotkoff Phase V) was taken as the diastolic
pressure. Information regarding a family history of hyperten-
sion was obtained by standardized questionnaires given to the
DCCT subjects.
Assessment of dietary intake of protein was performed using
a standardized diet history [14] obtained by the DCCT dietitian
and data analysis by the Central Nutrition coding Unit of the
University of Minnesota.
Subjects had no special dietary preparation prior to collecting
the four hour urine for Cr and albumin. Urine collection
generally began after the subjects had breakfast (without caf-
feine) and their morning dose of insulin. If the subject had a
hypoglycemic reaction the collection was delayed so that the
subject was without symptoms for at least one hour. The
collection was cancelled if a hypoglycemic reaction occurred
during the procedure; repeat testing was performed on another
day. Urine collections were obtained with the subjects resting
in a sitting position and abstaining from caffeinated beverages.
Subjects were asked to drink 250 ml of water every half hour
during the four hours. These carefully timed specimens were
collected on ice, mixed, their total volume measured and
aliquots frozen. Blood for S. was obtained during the second
two hours of the collection. The blood sample was allowed to
clot at room temperature; the serum was then separated and
frozen. Aliquots of the serum and urine specimens from each
DCCT center were sent in dry ice to the Central Biochemistry
Laboratory at the University of Minnesota for analysis. Creat-
mine was measured in serum and urine (Ur) according to an
automated kinetic method with the Jaffe reaction [15] and Ccr
calculated. Urinary AER in the same specimen was measured
with a solid-phase fluoroimmunoassay as has been previously
described [16]. The mean (± SD) urinary AER measured in 50
nondiabetic persons of comparable age to the study population
was 6.1 3.5 g/min with a range of 0.9 to 14.2 g/min [16, 17].
The fractional clearance of albumin relative to Ccr was calcu-
lated as (Ualb/PaIb)/(UCrIPCr) [18].
Clinical and laboratory quality control was monitored by
Table 1. Coefficients of variation and reliability of serum and urine
creatinine and albumin measurements
Variation
%
Reliabilitya
%
Serum
Albumin 3.3 77
Creatinine 4.4 85
Urine
Albumin 8.4 98
Creatinine 4,7 98
Albumin excretion rate 14.8 98
Creatinine clearance 6.9 88
a The proportion of the variance among the observed patient values
which is due to the variance among patients rather than owing to errors
in measurement [19].
analysis of masked split aliquots of approximately 10% of
patient specimens and comparing the results. The differences
between the resulting pairs were monitored over time via the
mean within-specimen coefficient of variation [19] and the
coefficient of reliability [20]. The data given in Table 1 are based
on the analysis of 591 split duplicates. The calculated values of
AER and Cr had higher coefficients of variation than the serum
and urine values but similar coefficients of reliability (Table 1).
About two years after initiation of the DCCT, '251-iothala-
mate clearance studies were performed on all new patients at
entry as an additional measurement of GFR. Because this
measurement was not obtained on all participants in the DCCT
at entry, this data will not be presented here but will be used in
future analyses of changes in renal function.
DCCT retinopathy grading system
Stereoscopic fundus photographs were obtained by certified
DCCT photographers as previously described [21]. The Modi-
fled Airlie House Classification of Diabetic Retinopathy [13]
was further modified for the DCCT to provide better discrimi-
nation at the level of minimal changes, as has been published in
detail [21]. Briefly, the retinopathy status of each eye was
individually graded with the following scale. A normal fundus is
graded at level 10. Level 20 indicates retinal microaneurysms
only. At level 30, the fundus has microaneurysms with one or
more of the following: hemorrhages, hard exudates, venous
ioops, questionable soft exudates (cotton-wool spots), ques-
tionable intraretinal microvascular abnormalities (IRMA) or
questionable venous beading. A fundus at level 40 has microan-
eurysms with mild but definite soft exudates and/or mild but
definite IRMA. Level 45 has microaneurysms with one of the
following: moderate soft exudates, moderate IRMA, retinal
hemorrhages/microaneurysms equaling or exceeding those in
standard photograph 2A [21] or any venous beading. Any
retinopathy excluded patients from the primary prevention
cohort. Retinopathy more severe than level 45 excluded a
subject from entry into the secondary intervention study.
Statistical analysis
The Wilcoxon rank sum test [22] was used to compare two
groups with respect to a continuous variable. For comparison of
dichotomous variables (such as gender), the continuity-adjusted
chi-square test for contingency tables was used [22]. Spearman
Rank Correlations estimated relationships between AER and
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Table 2. Baseline characteristics of the primary prevention cohort
and the secondary intervention cohort
Primary Secondary
Number of subjects 726 715
Age years 26 7 (14_37)a 27 7 (15—38)
Duration of IDDM 33 16 (14—59) 107 45 (27—172)
months
Serum creatinine 71 13 (53—88) 71 14 (53—97)
.unol/liter
Creatinine clearance 128 29 (89—178) 130 31(89—178)
ml/min/1.73 m2
Albumin excretion 8 6 (2—19) 14 17 (3—40)
rate g/min
Systolic BP mm Hg 113 11(94-132) 116 12 (98—134)
Diastolic BP mm Hg 73 8 (60—86) 74 9 (60—88)
Mean BP mm Hg 86 8 (73—99) 88 9 (73—101)
Hemoglobin A1 % 8.8 1.7 (6.6—12.0) 9.0 1.5 (6.8—11.9)
Gender % female 48 46
Smoking history % 36 35
Dietary protein 1.6 0.6 (0.9—2.6) 1.6 0.6 (0.8—2.6)
g/kg124 hr
Albumin fractional 0.2 0.1 (0.1—0.4) 0.3 0.3 (0.1—0.8)
clearance x iO
History urinary 18 19
infections %
Parental 40 40
hypertension %
Total cholesterol 4.51 0.87 (3.15—6.08) 4.62 0.84 (3.39—6.10)
mmol/liter
LDL cholesterol 2.78 0.77 (1.63—4.11) 2.90 0.74 (1.81—4.27)
mmol/liter
HDL cholesterol 1.34 0.33 (0.88—1.97) 1.28 0.30 (0.85—1.81)
mmollliter
Triglycerides 0.86 0.56 (0.42—1.54) 0.98 0.50 (0.49—1.98)
mmol/liter
a Results expressed as mean SD, with the 5th and 95th distribution
percentiles shown in the parentheses.
other measures of renal function and diabetes control. Logistic
multiple regression for a binary response variable was used to
assess the association of multiple covariates simultaneously
[23]. The proportional odds model [24] for ordinal data assessed
the association of multiple covariates simultaneously. The
skewed distribution of the AER and Cr prompted the use of a
natural logarithmic transformation in the latter models. Results
are expressed as means SD unless stated otherwise.
Results
Baseline characteristics of the primary prevention cohort and
the secondary intervention cohort are shown in Table 2. The
two cohorts were selected on different criteria and differ by
design with respect to duration and AER, so that specific
statistical tests for differences between the groups were not
performed. The two cohorts were similar with regard to diabe-
tes control on entry [hemoglobin (Hb) A1], gender, smoking
history, dietary protein intake, history of previous urinary tract
infections requiring antibiotics, history of hypertension in one
or both parents, total, LDL and high density lipoprotein (HDL)
cholesterol levels and triglyceride levels.
Baseline assessment of renal function in the primary
prevention cohort
Within the primary prevention cohort, all of whom were
selected to have a urinary AER of < 28 sgImin, the urinary
Table 3. Rank correlations of baseline urinary AER with other
parameters in the primary prevention and secondary intervention
cohorts
Parameter
Primary
prevention
Secondary
intervention
Creatinine clearance 0.26" 0.14"
Serum creatinine —0.11
Hemoglobin A1 019" 024b
Systolic BP 0.03 0.07
Diastolic BP 0.05 0.03
Mean BP 0.05 0.06
Duration 0.04 0.10
Age —0.08 —0.17"
Degree of retinopathya NA 0.20"
% of Ideal Body Weight —0.04 —0.04
a All patients in the primary cohort were free
baseline
See Methods section for definitions.
b P < 0.001
of retinopathy at
AER correlated positively with the and the HbAIC level
using Spearman Rank Correlations (Table 3). There were no
significant correlations between the urinary AER and systolic,
diastolic or mean BP, age or duration of IDDM.
Within the primary prevention cohort, there was no signifi-
cant difference in urinary AER between the sexes (males 8.3
6.1 g/min and females 8.1 5.4 pg/mm), although Ce,, was
significantly higher in males (131.8 29.0 vs. 123.0 28.2
ml/min/l.73m2, P < 0.001) as were systolic (116.6 11.0 vs.
109.9 10.3 mm Hg, P <0.001), diastolic (73.9 8.2 vs. 71.0
8.1 mm Hg, P < 0.001) and mean BP (88.1 8.1 vs. 84.0
7.9 mm Hg, P < 0.001). The HbA1ç was significantly lower in
males (8.6 1.6% vs. 9.1 1.7%, P < 0.001).
Baseline assessment of renal function in the secondary
intervention cohort
In the entire secondary intervention cohort, the urinary AER
correlated positively (P < 0.001) with the Car, HbAIC and
degree of retinopathy and negatively with age and there was a
borderline correlation with duration of IDDM (P = 0.007, Table
3). There was no significant difference in urinary AER between
the sexes (males 14.0 17.8 pg/mm and females 13.9 16.3
pg/mm). However, C was significantly higher in males (133.7
32.0 vs. 124.7 28.6 mlJminJl.73m2, P < 0.001) as were
systolic (119.4 10.6 vs. 111.4 11.1 mm Hg, P < 0.001),
diastolic (75.2 8.4 vs. 71.8 8.6mm Hg, P < 0.001) and mean
BP (89.9 7.9 vs. 85.0 8.4 mm Hg, P < 0.001).
Within the secondary intervention cohort, all of whom were
selected to have a urinary AER of 139 p.glmin, 89.8% of
subjects had urinary AER of < 28 pg/mm and 10.2% had
urinary AER  28 /sg/min (Fig. 1). One subject had an AER of
142 pg/mm and was included in the secondary cohort by error,
as the initial reading was thought to be < 139 pg/mm. Elevated
levels of AER were found in 12 individuals (16% of the total of
73 with increased AER) with less than five years duration of
diabetes (Fig. 1). These 12 subjects represented 8.6% of the
total of 140 subjects in this cohort who had a duration of  five
years of IDDM. Only one subject with duration  two years
had an AER level  28 pg/mm. There was a negative correla-
tion of urinary AER with age using Spearman Rank Correlation.
There were no significant correlations of urinary AER with
systolic, diastolic or mean BP within the secondary intervention
0' 10' 20 30 4d 5d 6d 7d 8d 9d iod iid
Albumin excretion, ug/min
cohort. In all of these assessments of correlations, the range of
the values were restricted because of selection criteria, that is,
they were curtailed by design.
Assessments of subjects in the secondary intervention cohort
with AER  28 pg/min
We compared the 73 subjects in the secondary intervention
cohort who had AER levels  28 g/min with the 626 subjects
with AER < 28 tgImin (Table 4). Although univariate analysis
using the Wilcoxon rank sum test or chi-square analysis sug-
gested (P < 0.05) that the subjects with AER  28 g/min had
higher mean blood pressure levels, lower age at baseline, lower
age at onset, lower stimulated C-peptide levels and higher
HbAIC and triglyceride levels, only the differences in mean
blood pressure and HbAIC levels were significant (P <0.005) by
logistic regression analysis after adjustment for other covari-
ates. There was no significant difference in Cr between the
subjects with AER < 28 gImin and those with AER  28
jgImin. There were no significant differences in LDL choles-
terol levels, history of prior urinary tract infections or parental
hypertension between these two groups.
Association of retinopathy with AER
Subjects in the secondary intervention cohort with AER < 28
g/min and  28 g/min were stratified by degree of retinopathy
at baseline (Table 5). A greater percentage (60.3%) of subjects
with AER  28 gImin were found to have more advanced
degrees of retinopathy (> level 20/20) than the subjects with <
28 p.g/min (only 34.6% with retinopathy > level 20/20) by
chi-square analysis (df = 3, P < 0.0001). As noted in Table 5,
the relative risk increase associated with microalbuminuria was
I I I I Fig. 1. Cumulative distribution of baseline
120 130 140 150 albumin excretion in the secondary
intervention cohort. 89.8% of subjects had a
urinary AER < 28 g/min.
present at every level of measurable retinopathy. This effect
persisted even when adjusted for duration of IDDM.
When subjects in the secondary intervention cohort were
stratified by retinopathy level and their AER's and other
parameters evaluated (Table 6), multivariate analysis indicated
significant (P < 0.001) associations between retinopathy level,
AER, duration of diabetes at entry and entry HbAIC. These
associations held even after accounting for each other in
addition to the other covariates listed in Table 6.
Discussion
The microvascular complications of diabetes, nephropathy
and retinopathy, appear to develop as a result of an interplay
between the abnormal metabolic milieu of diabetes and inde-
pendent genetic, environmental and developmental factors. The
DCCT, with its large numbers of subjects and relatively long
duration was designed to determine the effect of different
treatment modalities intended to produce different levels of
metabolic control on the appearance and progression of such
complications.
We have examined baseline parameters of renal function and
analyzed them as a function of glucose levels, concomitant
retinopathy and other established and putative risk factors. It
should be emphasized again that selection criteria were used at
the outset to delineate each cohort: the primary prevention
cohort had disease duration < five years, no hypertension, no
retinopathy and urinary AER < 28 g/min; the secondary
intervention cohort had disease duration 15 years, mild
retinopathy, no hypertension and urinary AER < 139 g/min.
In the secondary cohort only 10% of subjects had AER  28
g/min.
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Table 4. Characteristics of subjects in secondary intervention cohort with urinary AER < 28 g/min or urinary AER  28 sg/min
Urinary AER
Significancet'<28 /4g/min 28 sgImin
Number 642 73
Age at baseline years' 27 7 (15_38)a 26 7 (16—37) NS
Age at onset years 19 8 (7—31) 17 7 (7—29) NA
Gender % female 46 48 NS
Duration (mos)C 106 45 (26—172) 109 44 (35—170) NS
Systolic BP mmHg 115 12 (98—134) 118 11(102—138) NA
Diastolic BP mmHg 73 9 (60—88) 75 7 (64—88) NA
Mean BP mmHgc 87 9 (73—102) 90 7 (77—101) 0.003
Hemoglobin A1 %C 8.9 1.5 (6.8—11.7) 9.7 1.6 (7.0—12.5) 0.0001
Stimulated C-peptide nmol/literc 0.06 0.08 (0.0 1—0.22) 0.05 0.08 (0.01—0.27) NS
Serum creatinine pjnol/literc 71 14 (53—97) 69 11(53—88) NS
Creatinine clearancec 129 30 (88—176) 133 35 (100—196) NS
mi/mm/i .73m2
Smoking history %C 36 34 NS
Dietary protein g/kg/24 hrc 1.6 0.6 (0.8—2.6) 1.6 0.7 (0.8—2.9) NS
Albumin fractional clearance xiO 0.2 0.1 (0.1—0.5) 1.0 0.7 (0.4—2.8) NA
History urinary infection % 19 19 NA
Parental hypertension % 40 39 NS
Total cholesterol mmol/liter 4.61 0.85 (3.39—6.08) 4.74 0.79 (3.52—6.23) NA
LDL cholesterol mmol/literc 2.89 0.74 (1.81-4.27) 2.98 0.66 (2.12—4.14) NA
HDL cholesterol mmol/liter 1.28 0.30 (0.85—1.81) 1.25 0.28 (0.88—1,73) NS
Triglycerides mmoi/liter 0.96 0.49 (0.49—1.90) 1.16 0.54 (0.59—2.16) NA
% of ideal body weighte 105 12 (86—125) 105 12 (88—127) NA
a Results expressed as mean SD with the 5th and 95th distribution percentiles shown in the parentheses.b Adjusted p-values are calculated using Logistic Regression with a binary response variable, Abbreviations are: NS, not significant; NA, not
assessed.
C Covariates used in logistic regression. Other covariates were not used due to colinearity among the variables.
Table 5. Retinopathy level of subjects in secondary intervention
cohort with urinary albumin excretion of <28 g/min and 28 g/min
Retinopathy
levela
Urinary albumm excretion Relative
risk" 95% CIC<28 tg/min 28 g/min
20/20 420
(65.4%)
29
(39.7%)
1.0
30/30 126
(19.6%)
20
(27.4%)
2.12 (1.20, 3.75)
40/40 84
(13.1%)
18
(24.7%)
2.73 (1.52, 4.92)
45/45 12
(1.9%)
6
(8.2%)
5.16 (2.14, 12.43)
Total 642 73
a See text for definitionsb Retinopathy level 20/20 is taken as reference. The relative risk of
having an AER 40 mg/24 hr increases with increasing retinopathy
level. Test for homogeneity X2 = 22.88 (df = 3, P < 0.0001); test for
trend X2 = 21.54 (df = 1, P < 0.0001)
C 95% confidence interval
A number of investigators have proposed that minimal ele-
vations of urinary AER may be the earliest manifestation of
diabetic nephropathy based on studies of small numbers of
individuals with IDDM [9—12, 251. We therefore assessed the
prevalence of elevated AER levels in our subjects as well as the
association of AER with putative or established risk factors for
nephropathy. In both the primary prevention and secondary
intervention cohorts, the urinary AER correlated positively
with Ccr and HbA1C. Such a positive correlation of AER with
glycemic control has been noted previously [26—30] and has
been attributed to increased hydrostatic pressure and/or altered
membrane permeability [1, 2, 31, 32].
In the secondary intervention cohort there was a strong
rehitionship between the level of albumin excretion and more
advanced degrees of background retinopathy. Vigstrup and
Mogensen [33] previously reported that patients with microal-
buminuna had an almost tenfold increased risk of developing
proliferative retinopathy compared to those without microalbu-
minuria over a five year span following the development of
albuminuria. Other cross-sectional studies, such as the Pitts-
burgh Epidemiology of Diabetes Complications Study, have
also shown strong correlations between microalbuminuria and
background retinopathy as well as between overt nephropathy
and proliferative retinopathy [34]. These findings suggest that if
elevated AER levels truly reflect early nephropathy, common
factors may be involved in the pathogenesis of retinopathy and
nephropathy in their very early stages of development. Because
of these correlations early and late in the development of these
complications, it is likely that common pathogenetic factors con-
tinue to participate in the progression of the complications in
addition to hemodynamic factors, such as hypertension. Because
microalbuminuria has also been found to be highly correlated with
coronary artery disease [35], Deckert and colleagues at the Steno
Hospital have hypothesized that microalbuminuria may serve as a
marker for "widespread vascular damage [36]."
The positive correlation of levels of AER and retinopathy
with HbA1C in our crossectional data suggests that the meta-
bolic milieu may be one of the common factors involved in the
pathogenesis of these complications. It should be realized,
however, that HbA1 levels obtained at a single point in time
measures glycemic control for only the previous two to three
months, and thus may not reflect the prevailing metabolic
control for the duration of time during which nephropathy and
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Table 6. Measurement of baseline renal function according to baseline retinopathy level
Retinopathy level l0/10 20/20 30/30 45/45
Numberof subjects 726 449 146 120
Age years 26 7 (14—37)" 27 7 (15—38) 27 7 (15—38) 29 6 (18—38)
Duration of IDDM monthsc 33 16 (14—59) 94 44 (23—167) 123 36 (58—173) 133 37 (67—179)
Serum creatinine pinol/liter 71 13 (53—88) 72 14 (53—97) 69 13 (44—88) 72 15 (53—97)
Creatinine clearance 128 29 (89—178) 128 30 (85—176) 132 34 (91—199) 131 30 (93—176)
mi/mm/i .73m2
Albumin excretion ratec 8 6 (2—19) 12 12 (2—31) 16 19 (3—43) 21 26 (4—71)
/sg/min
Mean BP mm Hg 86 8 (73—99) 87 9 (73—101) 88 8 (74—101) 89 9 (73—103)
Hemoglobin Aie %C 8.8 1.7 (6.6—12.0) 8.9 1.5 (6.711.9) 9.0 1.4(6.8—11.4) 9.3 1.4 (7.2—12.0)
Subjects in primary cohort. Not included in statistical analysisb Results expressed as mean SD, with the 5th and 95th distribution percentiles shown in the parentheses.
'Significant at P < 0.001. A proportional odds model was used to account for the effect of multiple covariates on the level of retinopathy. AER
and Creatinine Clearance were transformed using a natural log. There were no significant differences in systolic BP, diastolic BP, gender, smoking
history, dietary protein intake, albumin fractional clearance, presence of parental hypertension, total, LDL or HDL cholesterol levels, triglyceride
levels or per cent ideal body weight between these groups classified by baseline retinopathy.
other microvascular complications develop. Furthermore, the
correlations were not strong and do not prove a cause and effect
relationship between glycemic levels and future renal insuffi-
ciency.
Within the secondary intervention cohort, there was a bor-
derline correlation of AER with duration of diabetes. Compar-
ison of our DCCT subject population may be made with the
population of 1888 normotensive patients with IDDM studied
by the Microalbuminuria Collaborative Study Group (MCSG)
[37] and the 679 similar subjects studied at the Steno Memorial
Hospital [38]. In both studies subjects with microalbuminuria
(>30 g/min and > 20 /Lg/min in the MCSG and Steno study,
respectively) had an increased duration of diabetes compared to
those without microalbuminuria. We found that 8.5% of DCCT
subjects in this 'ohoP with  five years duration and only one
subject with two years had AER levels  28 g/min. The
MCSG (which did not select patients on the basis of retinopathy
status) did not find microalbuminuria to be present before five
years duration of diabetes but the Steno study found 23% of their
subjects with duration <two years to have microalbuminuria.
Both the MCSG and Steno studies found that systolic and
diastolic BP's were higher in their subjects with microalbumi-
nuria; the DCCT only found a relation of AER with mean BP
and not systolic or diastolic BP. The Steno study and the
current study both found elevated AER levels to be associated
with higher HbA1C levels; this parameter was only assessed in a
subgroup by the MCSG and although a similar trend was found,
it was not statistically significant. These discrepancies may be
explained by the older age of the subjects (16 to 60 years in the
MCSG study and 18 to 50 years in the Steno study) and longer
durations of disease (up to 35 years in the MCSG study and up
to 48 years in the Steno Study), compared with the DCCT. In
addition, the MCSG and Steno studies had considerably higher
blood pressure exclusionary criteria (160/95 in the MCSG study
and "need for antihypertensive therapy" without specific nu-
merical criteria in the Steno study; 17% had BP > 140/90).
Thus, it is quite likely that the DCCT sample included people
with diabetes at a much earlier point along the path toward
developing possible nephropathy.
Some [39, 40] but not all [41] previous studies have reported
that the blood pressure was elevated in parents of diabetic
subjects with proteinuria compared to those without protein-
uria. We found no differences in the percentages of patients
with hypertensive parents when subjects in the secondary
cohort with AER < and  28 g/min were compared (Table 4).
Elevated LDL cholesterol levels have been reported in
patients with IDDM who have microalbuminuria in some stud-
ies but not others [42—44]. We found no significant differences in
LDL cholesterol levels when our patients in the secondary
cohort with AER < and  28 j.rg/min were compared.
In summary, we found that 10% of our subjects in the
secondary intervention cohort (selected to have minimal reti-
nopathy at baseline) had elevated AER levels. In both the
primary prevention and the secondary intervention cohorts
AER levels correlated positively with HbAIC levels. Within the
secondary intervention cohort there was a strong relationship
between elevated AER and more advanced degrees of diabetic
retinopathy. Within this cohort, subjects with AER levels  28
gImin had higher HbAIC and mean BP levels and longer
duration compared to those with AER levels < 28 g/min. The
relationships between progressive retinopathy, elevated AER
levels and HbAIC levels suggest that metabolic factors may be
present in the development and possibly progression of these
complications. The prospective prevention and intervention
studies of the DCCT, primarily designed to answer the question
of whether intensive diabetes treatment with the aim of normal-
izing glucose levels will affect the development and/or progres-
sion of retinopathy, may answer the same question with regard
to early nephropathy. The DCCT may also elucidate whether
the effects of intensive insulin therapy on retinopathy are
coordinated with treatment effects on the appearance and
progression of nephropathy in patients with IDDM.
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